"This is the peer reviewed version of the following article: [The Medical journal of Australia, 2020, 213, (7), pp. 327-328] which has been published in final form at

[https://onlinelibrary.wiley.com/doi/10.5694/mja2.50756] *purposes in accordance with Wiley Terms and Conditions for Self-Archiving.*"

## Implementing cardiovascular disease preventive care guidelines in general practice: an opportunity missed

Charlotte M Hespe<sup>1</sup>, Anna Campain<sup>2,3</sup>, Ruth Webster<sup>2</sup> (D), Anushka Patel<sup>2</sup>, Lucie Rychetnik<sup>1,4</sup>, Mark F Harris<sup>5,6</sup>, David P Peiris<sup>6</sup> (D)

ardiovascular disease (CVD) is the leading cause of death in Australia.<sup>1</sup> New treatment guidelines based on absolute CVD risk estimates were adopted in 2012.<sup>2</sup> General practitioners are central to implementing these guidelines, as about 90% of people in Australia consult GPs each year,<sup>3</sup> but large evidence-practice gaps in the management of people with CVD in general practice have been reported.<sup>4</sup>


We therefore examined implementation of the 2012 CVD guidelines in general practice by analysing baseline electronic medical record (eMR) data from two clinical trials of computer-supported interventions for improving CVD care conducted during 2015– 2018, the INTEGRATE<sup>5</sup> and Q Pulse studies.<sup>6</sup> Our analysis is based on data for 102 225 patients from 95 general practices in four Australian states and territories. The study was approved by the Human Research Ethics Committees of the University of Sydney (reference, 2015/616) and the University of Notre Dame (reference, 014105S/016011S).

De-identified eMR data – demographic information, medical history, prescribed medications, smoking status, blood pressure, low-density lipoprotein cholesterol (LDL-C) levels – were

extracted at each practice with the CAT 4 Clinical Audit tool (PenCS). Absolute CVD risk was calculated according to current guidelines<sup>2</sup> and patients with a documented CVD diagnosis (coronary heart disease, cerebrovascular disease, peripheral vascular disease, left ventricular hypertrophy, atrial fibrillation, or heart failure) were identified (Box 1).

Guideline-recommended treatment was defined as the prescribing of blood pressure- and lipid-lowering medications for patients at high CVD risk, and also of antiplatelet or anticoagulant medications for patients with established CVD (Supporting Information). The proportions of patients who had attained treatment targets for blood pressure (< 140/90 mmHg for patients at high CVD risk, < 130/80 mmHg for people with established CVD or diabetes) and LDL-C level (< 2.0 mmol/L) were calculated.

Of 102 225 patients in the two studies, 10 631 (10.4%) had established CVD and 12 983 (12.7%) clinically high risk conditions; estimated CVD risk was high for 2760 (2.7%) and low or intermediate for 46 205 people (45.2%), while the available eMR data were inadequate for estimating risk for 29 645 participants (29%).



diastolic blood pressure above 110 mmHg, or total cholester ollevel exceeding 7.5 mmol/L. 🔶

<sup>1</sup>The University of Notre Dame Australia, Sydney, NSW. <sup>2</sup>The George Institute for Global Health, Sydney, NSW. <sup>3</sup>University of New South Wales, Sydney, NSW. <sup>4</sup>The Australian Health Prevention Partnership, Sax Institute, Sydney, NSW. <sup>5</sup>Centrefor Primary Health Care and Equity, University of New South Wales, Sydney, NSW. <sup>6</sup>Office of the Chief Scientist, The George Institute for Global Health, Sydney, NSW. 🖂 charlotte.hespe@nd.edu.au • doi: 10.5694/mja2.50756

## 2 Prescribing practices and attainment of blood pressure and lipid targets for patients with established cardiovascular disease or at high risk of cardiovascular disease

-	Established cardiovascular disease	High cardiovascular disease risk
Number of patients	10631	15742
Medications prescribed		
No risk-lowering medications	2137 (20.1%)	3731 (23.7%)
Blood pressure-lowering medication only	1340 (12.6%)	3542 (22.5%)
Lipid-lowering medication (statin) only	1116 (10.5%)	1983 (12.6%)
All guideline treatments*	6038(56.8%)	6486 (41.2%)
Clinical targets achieved		
Blood pressure <sup><math>\dagger</math></sup>	4114 (38.7%)	8988 (57.1%)
Low-density lipoprotein cholesterol <sup>+</sup>	5645 (53.1%)	5714 (36.3%)

\*Oneormorebloodpressure-lowering medications and a statin; for people with established cardiovascular disease, either an antiplatelet or anticoagulant medication is also recommended (Supporting Information). † High cardiovascular disease risk: < 140/90 mmHg; established cardiovascular disease or diabetes: <130/80 mmHg. ‡ < 2 mmol/L. ◆

Among patients with established CVD, 6038 (56.8%) had been prescribed the guideline-recommended treatments; blood pressure targets had been achieved by 4114 patients (38.7%) and LDL targets by 5645 (53.1%). Among the 15 743 patients at high CVD risk, 6486 (41.2%) were prescribed recommended treatments;

- Australian Institute of Health and Welfare. Deaths in Australia. Updated 6 Aug 2020. https://www.aihw.gov.au/reports/life-expec tancy-death/deaths-in-australia/contents/leadi ng-causes-of-death (viewed Aug 2020).
- 2 National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. Apr 2012. http:// www.cvdcheck.org.au/pdf/Absolute\_CVD\_ Risk\_Full\_Guidelines.pdf (viewed May 2020).
- 3 Royal Australian College of General Practitioners. General practice: health of the nation 2018. Sept 2018. https://www.racgp.org. au/download/Documents/Publications/Healthof-the-Nation-2018-Report.pdf (viewed Aug 2020).

4 Webster RJ, Heeley EL, Peiris DP, et al. Gaps in cardiovascular disease risk management in Australian general practice. *Med J Aust* 2009; 191: 324–329. https://www.mja.com.au/journ al/2009/191/6/gaps-cardiovascular-disease-risk-management-australian-general-practice.

- 5 Joshi R, Patel A, Peiris D, et al. INTegrated Electronic General practice support tool, phaRmacy led intervention And combination Therapy Evaluation trial (INTEGRATE) [abstract]. *HeartLungCirc* 2015; 24 (Suppl 3): S385.
- 6 Hespe CH. Q Pulse. Reducing cardiovascular disease (CVD): translating an evidence based quality improvement tool into "real-world" general practice [ANZCTR registration: ACTRN 12615000108516]. Updated Jan 2018. https:// www.anzctr.org.au/Trial/Registration/Trial Review.aspx?id=367376&isReview=true (viewed May 2020).
- 7 Heeley EL, Peiris DP, Patel AA, et al. Cardiovascular risk perception and

8988 (57.1%) had achieved blood pressure targets and 5714 (36.3%) LDL-C targets (Box 1, Box 2).

Our findings indicate that primary care management of patients with CVD is sub-optimal. Adopting the absolute risk assessment approach has not improved adherence to management guide-lines,<sup>4,7</sup> similar to the experience in Europe, Canada, and the United Kingdom.<sup>8,9</sup>

We may have underestimated CVD risk for patients already receiving blood pressure- and lipid-lowering therapies. Risk estimates were based on information in eMR structured data fields; additional information recorded as free text was not considered. Rural and Aboriginal Medical Service practices were underrepresented in our practice sample.

GPs play essential roles in identifying patients at risk of CVD and managing their treatment,<sup>10</sup> but ensuring their adherence to evidence-based recommendations is challenging. While risk assessment tools are important, overcoming patient, GP, and health system barriers to changes in care delivery will be critical to progress.

Acknowledgements: The University of Notre Dame received a Bupa Health Foundation grant for research into cardiovascular disease and diabetes that funded the QPulse study and a quality improvement project in 46 practices in the Central and Eastern Sydney Primary Health Network. Ruth Webster is supported by a National Health and Medical Research Council (NHMRC) Early Career Fellowship (APP1125044), Anushka Patel by an NHMRC Principal Research Fellowship (APP1136898), and David Peiris by a Heart Foundation Future Leader Fellowship (101890) and NHMRC Career Development Fellowship (APP1143904).

**Competing interests:** George Health Enterprises, the social enterprise arm of the George Institute for Global Health, has received funding for the development of fixed dose combination therapy, and has commercial relationships involving digital

innovations similar to the interventions in the INTEGRATE study.

Received 21 September 2019, accepted 29 May 2020

© 2020 AMPCo Pty Ltd

evidence-practice gaps in Australian general practice (the AusHEART study). *Med J Aust* 2010; 192: 254-259. https://www.mja.com.au/ journal/2010/192/5/cardiovascular-risk-perce ption-and-evidence-practice-gaps-austr alian-general.

- 8 Nieuwlaat RSJ, Khatib R, Yusuf S. Why are we failing to implement effective therapies in cardiovascular disease? *Eur Heart J* 2013; 34: 1262.
- 9 Sheppard JP, Fletcher K, McManus RJ, Mant J. Missed opportunities in prevention of cardiovascular disease in primary care: a crosssectional study. Br J Gen Prac 2014; 64: e38–e46.
- 10 Berwick DM. Lessons from developing nations on improving health care. *BMJ*2004; 328:

1124–1129. 📕

## **Supporting Information**

Additional Supporting Information is included with the online version of this article.